Bold headline: Scotland faces a months-long shortage of prescription co-codamol, with supplies unlikely to return to normal before June. And this is the part most people miss: the impact isn’t just about a medicine being unavailable—it’s about how patients manage chronic pain when alternatives are stretched thin.
Overview
Scotland has confirmed that prescription-strength co-codamol, the strongest form of the commonly used painkiller, will be in short supply until the summer. The shortage affects the 30/500 mg dose, part of a UK-wide disruption tied to delays by the Indian government in authorising the import of ingredients needed to produce the drug there.
What this means for patients
- Alternative treatments will be offered to those affected, but health boards warn that no available substitute can fully match the demand expected.
- Some patients have been told by doctors that co-codamol won’t be available until June, prompting concerns about pain management and withdrawal risks for long-term users.
- One Gloucestershire example: Jocelin Harrison, a patient who has relied on co-codamol for more than 30 years due to pain from five spinal surgeries, was advised last week by NHS Lanarkshire to cut tablets by one per week to mitigate withdrawal effects. She reports receiving no information about possible alternatives.
What is co-codamol and why this matters
- Co-codamol combines codeine (an opiate) with paracetamol and comes in several strengths: 8 mg, 15 mg, or 30 mg of codeine, plus 500 mg of paracetamol per tablet.
- The lower-strength version is available from pharmacies without a prescription; higher strengths require a clinician’s prescription.
- Stopping suddenly can trigger withdrawal symptoms (headaches, nausea, sweating) and may worsen pain for heavy users unless a careful taper is followed.
Official guidance and current communications
- NHS Lanarkshire notes that other strengths exist, but the supply is insufficient to move everyone onto an alternative dose.
- The board states that all patients—except those undergoing cancer treatment—should gradually reduce use until stopping completely. No new prescriptions are being issued until supplies stabilize in June, though that date is not guaranteed.
- NHS Grampian has issued a similar message, urging pharmacists to use professional judgment to prioritize stock, but stops short of advising a nationwide taper for current users.
Underlying causes and responses
- Delays in India’s approval to import codeine-based active pharmaceutical ingredients (APIs) have contributed to the shortages, delaying production of co-codamol.
- Alison Struth, Scotland’s chief pharmaceutical officer, emphasised that medicine supply is a reserved matter for the UK government. She confirmed limited co-codamol supplies and said June 2026 is the expected timeframe for relief, while urging patients to rely on alternative treatments and avoid contacting GP practices or community pharmacies directly while workflows identify those affected.
- The UK Department of Health and Social Care reported that most licensed medicines remain in good supply, but acknowledged a current disruption for co-codamol due to manufacturing issues and ongoing work with suppliers and NHS clinicians to manage patients with guidance on alternatives.
Context on availability and manufacturing
- Generic, non-branded co-codamol tablets (including the 30/500 mg dose) are typically produced abroad, with production concentrated in places like China and India. Industry data indicate a broad export footprint for these APIs, underscoring the global nature of this supply chain.
Bottom line
- If you rely on co-codamol, stay informed through your health board’s official channels and discuss any pain-management concerns with your healthcare provider. The situation is evolving, and while alternatives exist, none are expected to fully replicate the demand or experience of co-codamol for every patient.
Question for readers
What are your experiences with managing chronic pain during medication shortages, and what strategies or alternatives have you found most helpful? Share your thoughts and questions in the comments.
